MedTrace Logo

Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis

NCT07291284 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 546

Last updated 2025-12-26

No results posted yet for this study

Summary

This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of LP-003 injection in patients with moderate to severe seasonal allergic rhinitis inadequately controlled by standard-of-care.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

BIOLOGICAL

LP-003

Participants were administered LP-003 via subcutaneous injection every 4 weeks.

BIOLOGICAL

Placebo

Participants were administered Placebo via subcutaneous injection every 4 weeks

Sponsors & Collaborators

  • Longbio Pharma

    lead INDUSTRY

Principal Investigators

  • Xueyan Wang · Beijing Shijitan Hospital, Capital Medical University (the formerly Beijing Railway General Hospital)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-01
Primary Completion
2026-03-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07291284 on ClinicalTrials.gov